About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group’s basic and clinical research activity, above all, surrounds the fields of inflammation and repair, respiratory insufficiency and tissue hypoxia, and these fields complement one another and are connected through the study of conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, infections, transplants, pulmonary hypertension or sleep-related breathing disorders.
The group has an experimental research laboratory and a clinical research and clinical trial unit. It is made up of professionals from different specialties (pulmonologists, biologists, nurses, laboratory technicians, physiotherapists etc.). This multidisciplinary team provides an added value to the group and guarantees the existence of the critical mass necessary to carry out scientific projects.
Our group is a node that belongs to the CIBERES network (CIBER for respiratory diseases) and also works in collaboration with groups of the highest national and international prestige.
IP: Mª Jesús Cruz Carmona Collaborators: MicroRNA expression profiles in asthmatic patients with different disease phenotypes exposed to pollutants. Funding agency: Instituto de Salud Carlos III Funding: 89900 Reference: FI22/00262 Duration: 01/01/2023 - 31/12/2027
IP: Maria Antonia Emilia Meneghini Collaborators: Lluis Castells Fusté, Joana Sellarés Roig, Jesús Quintero Bernabeu, Eva Maria Revilla Lopez, Marina Muñoz López, Meritxell Boada Perez, Laura Donadeu Casassas, Mercedes López González Funding agency: Instituto de Salud Carlos III Funding: 111320 Reference: PI22/00749 Duration: 01/01/2023 - 31/12/2025
IP: - Collaborators: Laura Campderros Traver, Eva Polverino Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI22/00887 Duration: 01/01/2023 - 31/12/2025
IP: Cristina Berastegui Garcia Collaborators: Carles Bravo Masgoret, Eva Maria Revilla Lopez, Meritxell Boada Perez, Susana Gómez Olles Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI22/01103 Duration: 01/01/2023 - 31/12/2025
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The new edition, led by Dr. Marc Miravitlles, updates treatment recommendations and integrates the consensus of the main medical societies involved in chronic obstructive pulmonary disease (COPD).
EXIMIOUS (Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome), un projecte finançat per la Unió Europea que engloba 15 organitzacions de 7 països europeus.
EXIMIOUS té com a objectiu estudiar l’exposoma, és a dir, l’exposició a factors ambientals al llarg de la vida, per entendre la seva relació amb les malalties immunomediades, com ara les malalties autoimmunes o les al·lèrgies. Des del VHIR està liderat per la Dra. M Jesús Cruz i el seu equip de Pneumologia.
